Update on "Open Study of the Catechol-O-Methyltransferase Inhibitor Tolcapone in Major Depressive Disorder"
Abstract
Hoffman-La Roche, Inc.; Nutley, New Jersey; Address e-mail to: [email protected] (Moroz) Hoffman-La Roche, Inc.; Basel, Switzerland (Magni) Massachusetts General Hospital; Boston, Massachusetts (Fava)
Integrity signals
Registry
Cites
Statistics
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
Pramipexole, piribedil, tolcapone, and amisulpride are effective in the treatment of MDD.
“Other examples of DA agents effective in the treatment of MDD include the selective D2/D3 receptor agonists pramipexole [292] and piribedil [293] the catechol-O-methyltransferase inhibitor tolcapone, [294], and the preferential presynaptic DA antagonist amisulpride, [295].”
From Reward circuitry dysfunction in psychiatric and neurodevelopmental disorders and genetic syndromes: animal models and clinical findings (2012) · cites this paper as [294]
Cites
Open Study of the Catechol-O-Methyltransferase Inhibitor Tolcapone in Major Depressive Disorder
D, M. F. M., Rosenbaum, J. F., Kolsky, A. R., Alpert, J. E., Nierenberg, A. A., Spillmann, M. K., Moore, C. M., Renshaw, P. F., Bottiglieri, T., Moroz, G., et al. (1999) · Journal of Clinical Psychopharmacology · doi:10.1097/00004714-199908000-00008 · Cited by 59 · see citing works
Self-citation
Flagged first, then by citations
Cited by
Sorted by citations
Hypomethylation of MB-COMT promoter is a major risk factor for schizophrenia and bipolar disorder
Abdolmaleky, H. M., Cheng, K.-H., Faraone, S. V., Wilcox, M., Glatt, S. J., Gao, F., Smith, C. L., Shafa, R., Aeali, B., Carnevale, J., et al. (2006) · Human Molecular Genetics · doi:10.1093/hmg/ddl253 · Cited by 462 · see citing works
Dichter, G. S., Damiano, C. A., & Allen, J. A. (2012) · Journal of Neurodevelopmental Disorders · doi:10.1186/1866-1955-4-19 · Cited by 299 · see citing works
- Authors
- Moroz, G., Magni, G., & Fava, M.
- Affiliations
- Massachusetts General Hospital (US)
- Venue
- Journal of Clinical Psychopharmacology
- Published
- 2000-04
- Volume
- 20
- Issue
- 2
- Pages
- 285
- ISSN
- 0271-0749 (ISSN-L)
- OpenAlex
- W4256324592
- Cited by
- 3
- References
- 1
- Citations by year
- 2014: 1 · 2012: 1
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Journal of Clinical Psychopharmacology (publishedVersion)
- Topics
- Health Sciences › Medicine › Pharmacology › Treatment of Major Depression
- Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Neurotransmitter Receptor Influence on Behavior
- Life Sciences › Neuroscience › Biological Psychiatry › Tryptophan and brain disorders
- Keywords
- tolcapone, catechol-O-methyltransferase inhibitors, major depressive disorder, antidepressant efficacy, COMT inhibition
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
